Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone vs N-acetylcysteine for prevention of post-embolization syndrome after TACE in hepatocellular carcinoma
TCTR20240816008Phase 3Unknown
- Sponsor
- Vajira Hospital Foundation
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexamethasone, acetylcysteine in post-embolization syndrome (PES), hepatocellular carcinoma (HCC), sponsored by Vajira Hospital Foundation. Status: unknown.
02
Drugs
dexamethasoneacetylcysteine
03
Conditions
post-embolization syndrome (PES)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on TCTR20240816008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240816008.